RU2010136988A - Антигенсвязывающие полипептиды против дегенерации хряща - Google Patents

Антигенсвязывающие полипептиды против дегенерации хряща Download PDF

Info

Publication number
RU2010136988A
RU2010136988A RU2010136988/10A RU2010136988A RU2010136988A RU 2010136988 A RU2010136988 A RU 2010136988A RU 2010136988/10 A RU2010136988/10 A RU 2010136988/10A RU 2010136988 A RU2010136988 A RU 2010136988A RU 2010136988 A RU2010136988 A RU 2010136988A
Authority
RU
Russia
Prior art keywords
binding polypeptide
antigen binding
polypeptide according
antigen
polypeptide
Prior art date
Application number
RU2010136988/10A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид УРЕХ (CH)
Дэвид УРЕХ
Петер ЛИХТЛЕН (CH)
Петер ЛИХТЛЕН
Original Assignee
Деленекс Терапьютикс Аг (Ch)
Деленекс Терапьютикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Деленекс Терапьютикс Аг (Ch), Деленекс Терапьютикс Аг filed Critical Деленекс Терапьютикс Аг (Ch)
Publication of RU2010136988A publication Critical patent/RU2010136988A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2010136988/10A 2008-02-05 2009-02-05 Антигенсвязывающие полипептиды против дегенерации хряща RU2010136988A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2631708P 2008-02-05 2008-02-05
US61/026,317 2008-02-05
US8887608P 2008-08-14 2008-08-14
US61/088,876 2008-08-14

Publications (1)

Publication Number Publication Date
RU2010136988A true RU2010136988A (ru) 2012-03-20

Family

ID=40568129

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010136988/10A RU2010136988A (ru) 2008-02-05 2009-02-05 Антигенсвязывающие полипептиды против дегенерации хряща

Country Status (10)

Country Link
US (1) US20110002927A1 (https=)
EP (1) EP2240515A1 (https=)
JP (1) JP2011510667A (https=)
CN (1) CN101939335B (https=)
AU (1) AU2009212079B2 (https=)
BR (1) BRPI0907485A2 (https=)
CA (1) CA2712965A1 (https=)
IL (1) IL206720A0 (https=)
RU (1) RU2010136988A (https=)
WO (1) WO2009097704A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540757A (ja) 2010-09-24 2013-11-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル
CN104231086B (zh) * 2013-08-27 2019-12-13 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
EP3081234B1 (en) * 2013-12-13 2020-04-08 Mercury Asset Management Co., Ltd. Articular cartilage imaging composition
US10568840B2 (en) * 2016-05-06 2020-02-25 The Brigham And Women's Hospital, Inc. Self assembled gels for controlled delivery of encapsulated agents to cartilage
CA3113948A1 (en) 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
CN120865334A (zh) * 2025-03-26 2025-10-31 中山大学附属第五医院 一种靶向软骨的阳离子肽类化合物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
NZ563580A (en) * 2005-06-07 2010-09-30 Esbatech An Alcon Biomedical R Stable and soluble antibodies inhibiting TNFaplha
JP2009542232A (ja) * 2006-07-10 2009-12-03 エスバテック・アーゲー 上皮および／または内皮層を通過するｓｃＦｖ抗体

Also Published As

Publication number Publication date
IL206720A0 (en) 2010-12-30
AU2009212079A1 (en) 2009-08-13
BRPI0907485A2 (pt) 2015-08-04
WO2009097704A1 (en) 2009-08-13
CN101939335B (zh) 2015-02-11
JP2011510667A (ja) 2011-04-07
CA2712965A1 (en) 2009-08-13
CN101939335A (zh) 2011-01-05
AU2009212079B2 (en) 2012-08-30
US20110002927A1 (en) 2011-01-06
EP2240515A1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
AU2014337367B2 (en) Peptidic chimeric antigen receptor T cell switches and uses thereof
US20180118808A1 (en) SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
JP2020536109A5 (https=)
RU2013141078A (ru) Одновалентные антигенсвязывающие белки
RU2012129735A (ru) Антитела к her3 и их применения
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA031209B9 (ru) Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
RU2010136988A (ru) Антигенсвязывающие полипептиды против дегенерации хряща
MX2012005864A (es) Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
JP2017534259A5 (https=)
US11666664B2 (en) Self assembling molecules for targeted drug delivery
EP3587440B1 (en) Human pd-l1 high-protein-affinity peptide and use thereof
IL273578B1 (en) Antibodies targeting pdl1 and methods of use thereof
WO2016207402A1 (en) Proteins comprising a mutated lair-1 fragment and uses thereof
CN118251406A (zh) 血管活性肠肽(vip)受体拮抗剂
CN117730143A (zh) 通过缀合的n-末端甘氨酸修饰的细胞及其用途
JP2011510667A5 (https=)
WO2021228052A1 (zh) 生物大分子靶向特异性补体抑制剂及其制备方法与应用
AR074398A1 (es) Anticuerpo nonoclonal o su fragmento de union a antigeno polinucleotido vector de expresion recombinante y celula huesped transformada correspondientes su uso para la preparacion de un medicamento util para el tratamiento o prevencion de anemia, composicion farmaceutica que lo comprende y proceso pa